Study design
This research project was conducted in Alicante General University
Hospital, Alicante, Spain, between November 2019 and January 2021. This
was a single centre, observational, non-randomized, retrospective,
non-comparative study analysing the effectiveness and safety of erenumab
and galcanezumab in the prevention of chronic or episodic migraine. The
study was approved by the institutional Ethics Committee (EREGAL-MI)
according to the STROBE checklist. All the patients enrolled in this
study were asked for their informed consent.